INTRODUCTION: Studies have explored whether spontaneous clearance of hepatitis C virus (HCV) infection decreases the likelihood of reinfection or increases the probability of clearance. This analysis investigates whether the conflicting findings from these studies could be due to differences in frequency of HCV RNA testing. METHODS: A model simulated the dynamics of HCV reinfection and clearance among a cohort of injection drug users. For different reinfection incidence and clearance rates, the model evaluated the accuracy of epidemiological studies that used different HCV testing frequencies. RESULTS: Experimental estimates for the reinfection incidence and clearance probability will be accurate (<20% error) if the testing interval is less than the reinfection clearance duration. Otherwise, experimental estimates can greatly underestimate the real values (≤66% error if reinfection duration is 1 month and the testing interval is 3 months). Uncertainty in experimental estimates also increases at lower reinfection incidences, whereas for lower clearance probabilities the uncertainty in the estimated clearance probability increases but estimated reinfection incidence decreases. DISCUSSION: Differences in HCV testing interval could account for most between-study variability in the estimated probability of clearing reinfections and is likely to have biased reinfection incidence estimates. Our findings suggest that a high reinfection clearance probability (>75%) is consistent with data.
INTRODUCTION: Studies have explored whether spontaneous clearance of hepatitis C virus (HCV) infection decreases the likelihood of reinfection or increases the probability of clearance. This analysis investigates whether the conflicting findings from these studies could be due to differences in frequency of HCV RNA testing. METHODS: A model simulated the dynamics of HCV reinfection and clearance among a cohort of injection drug users. For different reinfection incidence and clearance rates, the model evaluated the accuracy of epidemiological studies that used different HCV testing frequencies. RESULTS: Experimental estimates for the reinfection incidence and clearance probability will be accurate (<20% error) if the testing interval is less than the reinfection clearance duration. Otherwise, experimental estimates can greatly underestimate the real values (≤66% error if reinfection duration is 1 month and the testing interval is 3 months). Uncertainty in experimental estimates also increases at lower reinfection incidences, whereas for lower clearance probabilities the uncertainty in the estimated clearance probability increases but estimated reinfection incidence decreases. DISCUSSION: Differences in HCV testing interval could account for most between-study variability in the estimated probability of clearing reinfections and is likely to have biased reinfection incidence estimates. Our findings suggest that a high reinfection clearance probability (>75%) is consistent with data.
Authors: Michelina Nascimbeni; Eishiro Mizukoshi; Markus Bosmann; Marian E Major; Kathleen Mihalik; Charles M Rice; Stephen M Feinstone; Barbara Rehermann Journal: J Virol Date: 2003-04 Impact factor: 5.103
Authors: William O Osburn; Brian E Fisher; Kimberly A Dowd; Giselle Urban; Lin Liu; Stuart C Ray; David L Thomas; Andrea L Cox Journal: Gastroenterology Date: 2009-09-24 Impact factor: 22.682
Authors: J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: S C Hadler; D P Francis; J E Maynard; S E Thompson; F N Judson; D F Echenberg; D G Ostrow; P M O'Malley; K A Penley; N L Altman Journal: N Engl J Med Date: 1986-07-24 Impact factor: 91.245
Authors: Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker Journal: J Exp Med Date: 2003-06-16 Impact factor: 14.307
Authors: A Esmaeili; A Mirzazadeh; G M Carter; A Esmaeili; B Hajarizadeh; H S Sacks; K A Page Journal: J Viral Hepat Date: 2016-10-28 Impact factor: 3.728
Authors: Jason Grebely; Maria Prins; Margaret Hellard; Andrea L Cox; William O Osburn; Georg Lauer; Kimberly Page; Andrew R Lloyd; Gregory J Dore Journal: Lancet Infect Dis Date: 2012-05 Impact factor: 25.071
Authors: Rachel Sacks-Davis; Jason Grebely; Gregory J Dore; William Osburn; Andrea L Cox; Thomas M Rice; Timothy Spelman; Julie Bruneau; Maria Prins; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Janke Schinkel; Todd M Allen; Meghan Morris; Behzad Hajarizadeh; Lisa Maher; Andrew R Lloyd; Kimberly Page; Margaret Hellard Journal: J Infect Dis Date: 2015-04-15 Impact factor: 5.226
Authors: Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch Journal: Clin Infect Dis Date: 2012-10-22 Impact factor: 9.079
Authors: Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page Journal: Int J Epidemiol Date: 2012-11-30 Impact factor: 7.196